SELECTBIO - Next Generation Sequencing in the Clinic Asia Summit 2017 Biographies

Home

Agenda

Keynote Speakers

Registration

Exhibition

Venue

Training Courses

Co-Located Conferences

Detection of Previously Unidentified Structural Variants Involved in Glioblastoma Using PacBio® Sequel™ Sequencing

Thursday, 30 November 2017 at 15:00

Add to Calendar ▼2017-11-30 15:00:002017-11-30 16:00:00Europe/LondonDetection of Previously Unidentified Structural Variants Involved in Glioblastoma Using PacBio® Sequel™ SequencingNext Generation Sequencing in the Clinic Asia Summit 2017 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com

Glioblastoma is a devastating disease due in part to its often late-stage diagnosis, rapid progression, and poor survival rates. This casestudy looks at how GENEWIZ utilized the PacBio^® Sequel™ long-read technology to help a customer improve detection of structural variants within glioblastoma samples.

This Case Study discusses:

Generation of thousands of long-reads using PacBio Sequel Single Molecule Real Time (SMRT) technology
Generation of highly accurate consensus sequences
Identification of approximately 20,000 structural variants
Future applications

Jing Chen, NGS Business Line Leader, GENEWIZ China

Jing Chen graduated from Nanjing University, has 7 years of experience in the next-generation sequencing field with a variety of roles, ranging from bioinformatics analysis in BGI to business development and oversea market development in GENEWIZ. She is now serve as NGS business line leader in GENEWIZ China.